Drug news
US Court rules against Mylan that Zetia (Merck Inc.) patent is valid
A US Federal judge has ruled in two jointly related patent infringement suits against Mylan that a patent on hypolipaemic Zetia (ezetimibe) and related product Vytorin (ezetimibe plus simvastatin) from Merck Inc. is valid and has issued an injunction blocking the approval of generic versions by Mylan until the patent at issue expires 25 April 2017. Merck Inc.has agreed with Glenmark that the generic company can issue a generic version of exetimibe on 12 December 2016 or earlier according to "certain circumstances".
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins